LONDON, Feb. 17, 2020 /PRNewswire/ -- Arix
Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global venture
capital company focused on investing in and building breakthrough
biotech companies, today announces that one of its portfolio
companies, Imara Inc., ("Imara"), has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange
Commission (the "SEC") for a proposed initial public offering
("IPO") in the United States of
shares of its common stock. All shares to be sold in the offering
will be offered by Imara. Imara has applied to list its common
stock on the Nasdaq Global Market under the ticker symbol "IMRA".
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering. A further
announcement will be made in due course.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction. Any offers, solicitations or offers to buy, or any
sales of securities will be made in accordance with the
registration requirements of the Securities Act of 1933, as
amended.
The securities referred to in this release are to be offered
only by means of a prospectus. When available, copies of the
preliminary prospectus can be obtained from Morgan Stanley, 180
Varick Street, 2nd Floor, New York, New
York 10014, Attention: Prospectus Dept.; Citigroup, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York, 11717 or by
telephone at (800) 831-9146; or SVB Leerink, One Federal Street,
37th Floor, Boston, Massachusetts,
02110, Attention: Syndicate Department, by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@leerink.com.
This announcement includes information that is inside
information as defined in Article 7 of the Market Abuse Regulation
(EU) No.596/2014.The person responsible for arranging for the
release of this announcement on behalf of Arix Bioscience plc is
Robert Lyne, General
Counsel.
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated
to developing and commercializing novel therapeutics to treat
patients suffering from rare inherited genetic disorders of
hemoglobin, known as hemoglobinopathies. Imara is currently
advancing IMR-687, a highly selective, potent small molecule
inhibitor of PDE9 that is an oral, once-a-day, potentially
disease-modifying treatment for sickle cell disease and
beta-thalassemia. IMR-687 is being designed to have a multimodal
mechanism of action that acts on red blood cells, white blood
cells, adhesion mediators and other cell types.
Enquiries
For more information on Arix, please
contact:
Arix Bioscience plc
Charlotte
Parry
Head of Investor Relations
+44(0)20-7290-1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark
Supriya Mathur
+44(0)20-3714-1787
optimum.arix@optimumcomms.com
View original
content:http://www.prnewswire.com/news-releases/arix-bioscience-plc--imara-files-for-proposed-initial-public-offering-in-the-united-states-301005809.html
SOURCE Arix Bioscience plc